United Therapeutics Corporation  

(Public, NASDAQ:UTHR)   Watch this stock  
Find more results for UTHR
167.18
+1.22 (0.74%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 164.07 - 168.50
52 week 86.04 - 190.29
Open 166.32
Vol / Avg. 714,474.00/598,551.00
Mkt cap 7.67B
P/E 52.46
Div/yield     -
EPS 3.19
Shares 45.54M
Beta 1.46
Inst. own 116%
Oct 26, 2015
Q3 2015 United Therapeutics Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 28, 2015
Q2 2015 United Therapeutics Corp Earnings Release
Jul 28, 2015
Q2 2015 United Therapeutics Corp Earnings Call
Jun 26, 2015
United Therapeutics Corp Annual Shareholders Meeting
Jun 4, 2015
United Therapeutics Corp at Jefferies Global Healthcare Conference
May 6, 2015
United Therapeutics Corp at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 28.58% 26.39%
Operating margin 49.46% 41.82%
EBITD margin - 44.32%
Return on average assets 21.92% 17.12%
Return on average equity 36.75% 26.47%
Employees 740 -
CDP Score - -

Address

1040 SPRING ST
SILVER SPRING, MD 20910
United States - Map
+1-301-6089292 (Phone)
+1-301-6089291 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Company’s lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Officers and directors

Martine A. Rothblatt Ph.D., J.D. Chairman of the Board, Co-Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Roger Jeffs Ph.D. President, Co-Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Christopher Patusky J.D. Lead Independent Vice Chairman of the Board
Age: 51
Bio & Compensation  - Reuters
John M. Ferrari Ph.D. Chief Financial Officer, Treasurer
Age: 60
Bio & Compensation  - Reuters
David Zaccardelli Pharm.D Chief Operating Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Paul A. Mahon J.D. Executive Vice President, General Counsel, Corporate Secretary
Age: 51
Bio & Compensation  - Reuters
Raymond A. Dwek Non-Independent Director
Age: 73
Bio & Compensation  - Reuters
Katherine J. Klein Ph.D Director
Age: 58
Bio & Compensation  - Reuters
Raymond C. Kurzweil J.D. Non-Independent Director
Age: 67
Bio & Compensation  - Reuters
Christopher Causey Independent Director
Age: 51
Bio & Compensation  - Reuters